How do GLP-1 agonists (Ozempic Wegovy Mounjaro) effect heart rate and heart rate variability?

Does Your Heart Rate Go Up on GLP-1 Drugs? Peter Attia Breaks It Down

If you track your resting heart rate or wear a fitness watch, you may have noticed something odd after starting semaglutide or tirzepatide: your heart rate went up. Maybe 5 beats per minute. Maybe 10. And your heart rate variability (HRV), which health optimizers treat like a vital sign, may have dropped.

That is unsettling. Especially when you are taking a drug partly for its cardiovascular benefits.

Peter Attia, a physician who focuses on longevity and metabolic health, tackles this question directly. His take is measured, grounded in data, and useful for anyone who has been staring at their wearable data wondering if something is wrong.

The Heart Rate Increase Is Real

Clinical trial data from the STEP and SUSTAIN programs show a consistent finding: people on semaglutide tend to see a small increase in resting heart rate. The average bump is around 2 to 4 beats per minute in trials, though some individuals report higher increases.

This is not unique to Ozempic. Tirzepatide (Mounjaro) shows the same pattern. And it is not new information. Researchers have known about this since the early trial phases. The question has always been: does it matter?

Attia points out that a small heart rate increase, in isolation, is not necessarily a red flag. Heart rate responds to dozens of variables. Dehydration, reduced caloric intake, changes in body composition, and autonomic nervous system shifts can all move the needle. When you lose significant weight rapidly, your body recalibrates a lot of systems at once.

HRV Tells a More Complicated Story

Heart rate variability is the beat-to-beat variation in your heart rhythm. Higher HRV generally signals a well-functioning autonomic nervous system, good recovery, and lower stress. Lower HRV is associated with worse cardiovascular outcomes over time.

Some GLP-1 users have reported drops in HRV, and that has generated concern in health-tracking communities. Attia addresses this carefully. He notes that HRV is highly individual and influenced by sleep, stress, hydration, caloric deficit, and exercise. A person losing 15% of their body weight is going through major physiological change. Expecting stable HRV during that process is unrealistic.

The key distinction Attia draws is between short-term fluctuation and long-term trend. A temporary dip in HRV during active weight loss is different from a sustained drop that continues after weight stabilizes. The former is expected. The latter would be worth investigating.

But the Cardiovascular Outcomes Data Is Reassuring

Here is where the picture gets interesting. Despite the heart rate bump, the SELECT trial (a major cardiovascular outcomes study) showed that semaglutide reduced major adverse cardiac events by 20% in people with established cardiovascular disease and obesity. That includes heart attacks, strokes, and cardiovascular death.

So the drug slightly raises heart rate in the short term, but significantly reduces heart disease risk over the long term. Attia frames this as a net-positive tradeoff, at least for the population studied in SELECT.

This is an important nuance. The cardiovascular benefits appear to come from reduced inflammation, improved metabolic markers, lower blood pressure, and better lipid profiles. Those factors outweigh the small heart rate increase in most clinical contexts.

When Should You Actually Worry?

Attia is clear that certain situations warrant a conversation with your doctor. If your resting heart rate has jumped by 15 or more beats per minute. If you are experiencing palpitations, dizziness, or shortness of breath. If you have a pre-existing arrhythmia or heart condition. These are not things to ignore.

For most people, though, a 3 to 7 beat increase in resting heart rate while actively losing weight on a GLP-1 is not a danger signal. It is a physiological response to a drug that is changing how your body processes energy, regulates appetite, and manages inflammation.

The Wearable Data Problem

One thing Attia touches on that deserves attention: consumer wearables have made everyone hyper-aware of metrics they do not always have context for. A single morning HRV reading is noisy. A single resting heart rate measurement can vary by 10 BPM based on whether you had caffeine, how well you slept, or if you are fighting off a mild cold.

Trends over weeks and months matter more than any single data point. If you are tracking your health data on a GLP-1, look at the 30-day moving average, not yesterday's reading. That approach will give you a much clearer picture of whether something meaningful has changed.

A Closer Look at the SELECT Trial Numbers

The SELECT trial deserves a closer look because it is the strongest evidence that a small heart rate bump does not translate into worse outcomes. This was a randomized, double-blind study of over 17,600 adults with established cardiovascular disease and a BMI of 27 or above. None had diabetes, which means the cardiac benefits were more than a byproduct of better blood sugar control.

Over roughly 40 months, semaglutide at 2.4 mg weekly reduced the combined rate of cardiovascular death, nonfatal heart attack, and nonfatal stroke by 20%. C-reactive protein dropped significantly. So did blood pressure and visceral fat. The heart rate went up a few beats, but nearly every other cardiac risk factor improved. That is the tradeoff Attia keeps coming back to.

Practical Steps if Your Heart Rate Is Stressing You Out

Check your hydration first. GLP-1 drugs suppress appetite, and many people drink less water when they eat less food. Dehydration alone can push resting heart rate up by 10 BPM.

Look at how fast you are losing weight. A steep caloric deficit raises cortisol and sympathetic nervous system activity, both of which increase heart rate. If you are dropping more than 2 pounds per week, the deficit may matter more than the drug itself.

Keep doing zone 2 cardio. Easy, conversational-pace exercise trains your parasympathetic nervous system and is one of the best tools for keeping resting heart rate healthy long term.

Get bloodwork before starting and again at 3 and 6 months. Thyroid function, a basic metabolic panel, and hs-CRP give you and your doctor real data instead of guessing from wrist-sensor readings.

What the Video Gets Right and Where It Simplifies

Attia nails the core message: a small heart rate increase on GLP-1 drugs is not, by itself, a reason to panic. The SELECT trial data backs this up convincingly. He also does a good job explaining that wearable data needs context, something that most fitness-tracking communities get wrong.

Where the video simplifies is on the question of who should worry. Attia is speaking to a general audience, but cardiac risk is highly individual. A 3-BPM increase means something very different for a 35-year-old with no cardiac history than for a 62-year-old with atrial fibrillation. The video could have spent more time on pre-existing cardiac conditions and how they change the risk calculus.

He also does not address the thyroid connection. GLP-1 drugs carry a boxed warning about medullary thyroid carcinoma risk based on rodent data, and thyroid dysfunction can independently affect heart rate. If your heart rate jumps and your thyroid function is off, the drug might not be the primary cause. Getting thyroid levels checked is a simple step that Attia does not mention but that matters for differential diagnosis.

How Other FormBlends Videos Add to This Picture

If heart rate changes have you concerned, the Institute of Human Anatomy video on what Ozempic does to the body provides the anatomical context for why GLP-1 receptors exist in cardiac tissue. Seeing the physical structures involved helps you understand that the heart rate effect is not a side effect in the traditional sense. It is the drug interacting with receptors that are supposed to be there.

The mental health effects video from Dr. Josef is relevant here too, though the connection is not obvious at first glance. Anxiety about health metrics, especially from wearable data, can itself raise heart rate and lower HRV. If you are checking your heart rate every hour because you are worried about your heart rate, you are creating a feedback loop that makes the numbers look worse than they are.

For people whose heart rate concerns are tied to exercise performance, the muscle preservation video from Dr. Dan covers training strategies that include zone 2 cardio, the same type of exercise Attia recommends for keeping resting heart rate healthy.

Questions to Bring to Your Cardiologist or Prescriber

If your heart rate data is making you uneasy, these are questions worth raising at your next visit.

"My resting heart rate has gone from X to Y since starting semaglutide. Is that within the expected range?" Give your doctor specific numbers and a timeframe. Vague concerns are hard to address. Specific data points are not.

"Should we get a baseline EKG or echocardiogram before continuing?" For most healthy adults, this is probably unnecessary. But if you have a family history of heart disease or any prior cardiac issues, it is a reasonable request.

"Could the heart rate change be related to dehydration or caloric deficit rather than the drug itself?" This shows your doctor you are thinking about confounding factors, and it may lead to practical advice about hydration and nutrition that solves the problem without medication changes.

"At what point would you consider adjusting the dose or switching medications based on heart rate?" Knowing your doctor's threshold in advance helps you monitor with purpose rather than anxiety.

The Bottom Line

GLP-1 drugs do raise heart rate slightly. They may temporarily lower HRV during active weight loss. Neither of these findings, based on current evidence, negate the strong cardiovascular benefits these drugs provide for people with obesity and metabolic disease. But individual variation matters. Track your data, look at trends, and bring concerns to a physician who understands both the drug and the data.